Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: exosome-delivered cancer therapeutics - EXO Biologics

X
Drug Profile

Research programme: exosome-delivered cancer therapeutics - EXO Biologics

Latest Information Update: 28 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EXO Biologics
  • Class Antineoplastics; Exosome therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 12 Jun 2024 EXO Biologics has patents pending for extracellular vesicles (EVs) derived from mesenchymal stromal cells and method for obtaining said EVs in Australia, Japan, Europe, Israel, Canada, South Korea, USA, China, Mexico, Brazil and worldwide
  • 12 Jun 2024 EXO Biologics has patents pending for extracellular vesicles and compositions thereof in USA, Europe and worldwide
  • 12 Jun 2024 EXO Biologics has patents pending for process for the manufacturing of protein-associated extracellular vesicles in Europe, Mexico, South Korea, Canada, Israel, Australia, China, USA, Japan, Brazil and worldwide
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top